Trividia Health Announces Jonathan Chapman as President and Chief Executive Officer
15.9.2021 11:00:00 EEST | Business Wire | Press release
Trividia Health, Inc., a leading supplier of blood glucose monitoring systems, announced today that Jonathan Chapman has been appointed as President and Chief Executive Officer. Mr. Chapman succeeds Scott Verner in the role.
Mr. Chapman brings over 20 years of leadership experience in the medical device industry, with an accomplished track record of driving growth, developing strategic alliances, launching products globally, and optimizing business operations.
In addition to his newly assumed responsibilities at Trividia Health, Mr. Chapman will continue to serve as President and Chief Executive Officer of PTS Diagnostics, Inc.
“Jonathan has proven himself as the right leader for PTS Diagnostics and is the right leader for Trividia,” said Shaobo Li, Chairman of the Board at both Trividia Health and PTS Diagnostics. “Jonathan’s extensive background in successfully running medical device companies and his business development skills will help both organizations to reach the next level of growth and evolution. Jonathan is a results-oriented, dynamic, and innovative business leader. I am confident he has the right track record, commitment, vision and judgment to lead Trividia and PTS Diagnostics.”
“I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes,” said Jonathan Chapman, President and CEO of Trividia Health and PTS Diagnostics. “I look forward to working with my colleagues at Trividia. With their support, focus on customers and continuing dedication, we will build on Trividia’s legacy of bringing leading innovation to patients across the globe.”
Mr. Chapman received a Bachelor of Arts from Sheffield University UK, LLM Commercial and Corporate Law from University of London (SOAS) and LLM Health Law from Hamline Law School, St. Paul, MN. Trividia is confident that his international experience will be immensely valuable when leading the organization across global markets.
About Trividia Health
Trividia Health, Inc., is a global health and wellness company with over 30 years experience in the industry. Based in Fort Lauderdale, Florida, Trividia is a leading developer, manufacturer and marketer of advanced performance products for people and pets with diabetes. With products sold under the TRUE brand, store brand labels and Healthy Tracks for Pets, the company is the exclusive partner and supplier of affordable, high-quality blood glucose monitoring and health and wellness solutions for the world’s leading retail pharmacies, distributors and mail service providers. For more information, please visit: www.TrividiaHealth.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005226/en/
Contact information
Neal Bhattacharya, Sr. Director, Product Marketing
(800) 342-7226, ext. 3150 – nbhattacharya@trividiahealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer11.8.2026 15:30:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Officer at Vaxcyte; Suha Jhaveri, former Strategic Advisor at Cidara before its acquisition by Merck; and Bill Warren, former Global Head of Antigen Design at Sanofi Vaccines, as independent members of ILiAD’s Board of Directors. The Company also announced the appointment of Antony Blanc, former VP, Head of Global Marketing and Global Strategic Pricing at GSK Vaccines, as Chief Business Officer. “Our recently appointed colleagues bring an extraordinary depth of experience in vaccine development, global commercialization, and strategic growth,” said Keith Rubin, MD, Founder and Chief Executive Officer of ILiAD. “As we advance BPZE1 to the next pivotal phase of ILiAD’s growth, the insights and leadership of Antony, Bill, Jim and Suha will be invaluable in
TEC reduces pressure on support teams with proactive outage communications powered by Adtran and GOCare11.8.2026 15:15:00 EEST | Press release
Adtran and GOCare today announced that Telephone Electronics Corporation (TEC) has improved outage responses and reduced inbound support tickets using GOCare’s OutageIQ solution integrated with Adtran’s outage notification API and Mosaic One. Serving communities across Mississippi, Alabama and Tennessee, TEC delivers fiber broadband services built on a foundation of community investment and reliable service. By combining proactive notifications with real-time network insights, the service provider can now inform customers as issues are detected while equipping support teams with immediate context. This transparency helps build subscriber trust and streamlines operations. “Reliable connectivity is essential for the communities we serve, and clear communication during an outage makes a real difference,” said David Freytag, VP of integration at TEC. “Before this integration, service disruptions could quickly lead to high call volumes, putting pressure on our teams and leaving subscribers
Kinaxis-Sponsored Study Identifies Supply Chain AI Accountability Gap Amidst Rapid Adoption Expectations11.8.2026 15:07:00 EEST | Press release
Kinaxis® (TSX:KXS), a global leader in supply chain orchestration, today announced the findings of new independent research from IDC. The IDC InfoBrief, sponsored by Kinaxis, “Making Supply Chain AI Accountable,” reveals a growing chasm between organizations’ aggressive ambitions for autonomous AI adoption and their readiness to hold these advanced systems - which we believe underscores the need for a disciplined approach to AI investment and deployment to prevent costly failures and deliver measurable business value. What This Means for Supply Chain Leaders The IDC InfoBrief, which surveyed more than 2,000 supply chain leaders across nine global markets, found that while AI adoption is nearly universal - only 2% of respondents report no AI-enabled capabilities, and just 12% consider themselves AI leaders. Over half (52%) cite trust in AI-driven decisions as a top barrier to faster adoption, and just 12% say AI planning governance is fully embedded within their operations. The research
One in Four Executives Say AI Errors Have Reached External Audiences or Boards, According to New Research From Workiva11.8.2026 15:00:00 EEST | Press release
Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, today released findings from its 2026 Midyear Executive Benchmark Survey. Although 84% of surveyed executives say they are at least somewhat confident in the accuracy of AI output without human review, one in four (26%) say internal audits have detected AI errors that reached external audiences or board members. This data suggests there is a disconnect between what executives believe and what evidence shows. As AI reshapes the enterprise at unprecedented speed, a new risk is emerging: transformation could be outpacing the instincts of the leaders tasked with overseeing it. "Confidence in AI without control over data quality is a liability, not a strategy. CFOs need platforms that connect AI to trusted, auditable data so every output is one they can verify and every disclosure is one they can defend," said Barbara Larson, Chief Financial Officer at Workiva. "Getting this right is about
Altasciences Continues to Expand North American Bioanalytical Footprint11.8.2026 15:00:00 EEST | Press release
Altasciences today announced a major expansion of its North American bioanalytical laboratory footprint, reinforcing its commitment to helping sponsors accelerate drug development through increased capacity, advanced automation, and harmonized scientific operations. The expansion includes a 4,000-square-foot addition to the company’s laboratory in Greater Montréal, which is expected to be fully operational by the end of Q3 2026. The company has also announced a new 13,000-square-foot purpose-built laboratory in Harleysville, Pennsylvania. Construction will proceed in phases, with Phase 1 scheduled for completion in Q1 2027. These investments significantly increase Altasciences' ability to support the growing demand for late-stage clinical bioanalysis while providing sponsors with greater flexibility, scalability, and operational resilience. Designed to support increasingly complex development programs, the expanded laboratories will result in increased capacity to conduct larger studie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom